18 results
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
the submission and regulatory acceptance of INDs, trial protocols and design, patient recruitment and enrollment, quality and supply of clinical doses … of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. Drug-related side effects could affect patient recruitment
POS AM
IKT
Inhibikase Therapeutics Inc
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
surrounding the submission and regulatory acceptance of INDs, trial protocols and design, patient recruitment and enrollment, quality and supply … recruitment, the ability of enrolled patients to complete the study, and/or result in potential product liability claims. We are required to maintain
424B4
rmzqbahjg vi6hikjf5p
17 Jun 21
Prospectus supplement with pricing info
4:31pm
DRS
uuavuc38
2 Jun 21
Draft registration statement
12:00am
10-K
dx1b2mqr4ida1q
31 Mar 21
Annual report
2:14pm
424B4
gy026ti
28 Dec 20
Prospectus supplement with pricing info
6:04am
S-1
jqsj v2q8h4gondx
23 Jul 20
IPO registration
12:28pm
DRS/A
gx9dkp gvb2e5y
16 Oct 18
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next